Trial ID or NCT#

NCT01387932

Status

NOT RECRUITING

Purpose

The purpose of this study is to evaluate overall survival in patients treated with HepaSphere/QuadraSphere compared to conventional transarterial chemoembolization with particle PVA.

Official Title

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Daniel Sze, MD, PhD
Interventional radiologist
Professor of Radiology (General Radiology) at the Stanford University Medical Center
Lawrence "Rusty" Hofmann, MD
Interventional radiologist
Professor of Radiology (General Radiology) at the Stanford University Medical Center
David Hovsepian, MD
Interventional radiologist, Radiologist
Clinical Professor, Radiology
Gloria Hwang, MD
Interventional radiologist
Clinical Associate Professor, Radiology
John D. Louie, MD
Interventional radiologist
Clinical Associate Professor, Radiology
WILLIAM T. KUO, MD, FSIR, FCCP, FSVM, FCIRSE
Interventional radiologist
Associate Professor of Radiology (General Radiology) at the Stanford University Medical Center
Nishita Kothary, MD
Interventional radiologist
Associate Professor of Radiology (General Radiology) at the Stanford University Medical Center
David S. Wang, MD
Interventional radiologist, Radiologist
Clinical Assistant Professor, Radiology
Rajesh Shah, MD
Interventional radiologist
Clinical Assistant Professor (Affiliated) [VAPAHCS], Rad/Interventional Radiology Staff, Radiology - Diagnostic Radiology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061